Svetlana A Limborska
Institute of Molecular Genetics, Russia
Title: Pharmacogenomics of peptide drugs
Biography
Biography: Svetlana A Limborska
Abstract
The application of pharmacogenomics approaches has become an integral part in the drug development. This report will demonstrate the notable examples of using pharmacogenomics to clarify the mechanism of action of compounds based on natural regulatory peptides. Genome-wide transcriptome analysis was employed to search gene expression alterations under Semax and Selank impact. Semax has neuroprotective and nootropic effects without hormone action. Semax used for the treatment of cerebral ischemia, stroke, traumatic brain injuries, Parkinson’s, Alzheimer’s and other diseases. The study of Semax action on the transcriptome of rat brain cells under experimental ischemia conditions has identified large-scale changes in gene expression, including genes, which provide functioning of immune and vascular systems. Selank has anti-anxiety effect, normalizes the emotional state, and also has antiviral activity. Selank used in neurology, pediatrics and for the treatment of viral diseases. We revealed the change in mRNA level of many genes in the rat hippocampus after Selank administration including genes involved in neurotransmission. The transcriptome analysis of mouse spleen cells after Selank treatment revealed many genes changing their expression including genes of immune system. Thus, the transcriptome analysis showed important influence of regulatory peptide drugs on cellular metabolism that may determine their positive effect on the treatment of the relevant diseases.
